HighGravityDataInsulet — Feb 18, 2026 release
Fiscal 2025 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001145197-26-000026
Showing in the filing
International
“24% -26%”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 11
Share repurchase authorization increase
“$350 million”
Planned share repurchases for Q1 FY2026
“approximately $300 million”
Repurchases for Q1 FY2026
“approximately $300 million”
International for Q1 FY2026
“37% - 39%”
Total Omnipod Products for Q1 FY2026
“28% - 30%”
Total Omnipod Products for FY2026
“21% - 23%”
Drug Delivery for Q1 FY2026
“~(80)%”
Adjusted Operating Margin for FY2026
“~100 bps YoY expansion”
Adjusted EPS Growth for FY2026
“>25%”
Drug Delivery for FY2026
“~(50)%”
International for FY2026
“24% -26%”
Exhibit 99.1 · the passage around this item
… earlier in the release
20% - 22% —% 20% - 22% International 27% - 29% 3% 24% - 26% Total Omnipod Products 22% - 24% 1% 21% - 23% Drug Delivery ~(50)% —% ~(50)% Total 21% - 23% 1% 20% - 22% Three Months Ending March 31, 2026 Revenue Growth GAAP Currency Impact Constant Currency U.S. 24% - 26% —% 24% - 26% International 48% - 50% 11% 37% - 39% Total Omnipod Products 30% - 32% 2% 28% - 30% Drug Delivery ~(80)% —% ~(80)% Total 27% - 29% 2% 25% - 27% 12
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.